Latest Breaking News On - Amitg singal - Page 1 : vimarsana.com

Combined therapy makes headway for liver cancer

A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without

United statesYujin hoshidaEugenep frenkelPaula calvertJay lohreyRadhika kainthlaChul ahnJakel hamonLeticia khosamaAmitg singalPeter odonnell jrEllen siglinskyAdamc yoppHeather klineWillisc maddreyDavid hsieh

Combined therapy makes headway for liver cancer

A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without

United statesPaula calvertEugenep frenkelYujin hoshidaJay lohreyLeticia khosamaJakel hamonChul ahnRadhika kainthlaPeter odonnell jrAmitg singalAdamc yoppEllen siglinskyHeather klineDavid hsiehWillisc maddrey

HCC screening linked to reduced mortality but remains underused in clinical practice

HCC screening linked to reduced mortality but remains underused in clinical practice
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaBykate burbaHeather bieleAmitg singalUt southwestern medical centerMedical centerBarcelona clinical liver cancer

Real-World Data Show High Discontinuation Rates for Frontline Atezolizumab/Bevacizumab in HCC

Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease.

United statesAmitg singalDepartment of internal medicineInternational liver cancer association conferenceUt southwestern medical centerLiver cancer associationInternal medicineMedical centerSource medicalCharlson comorbidity indexGastrointestinal cancerHepatocellular carcinoma

Study shows link between liver transplant survivor s recovery and sociodemographic factors

The resilience and coping abilities of patients who've had liver transplants vary and change over time and are often linked to sociodemographic factors including income, race, and education, a study led by UT Southwestern Medical Center researchers shows.

United statesWillisc maddreyAlvaro noriega ramirezSarahr lieberAmitg singalEmily hendersonHaroldc simmons comprehensive cancer centerUt southwestern fund to retain clinical scientistsFund to retain clinical scientistsDoris duke charitable foundationLiver tumor programClinical researchDivision of digestiveAmerican heart associationUt southwestern medical centerUniversity of north carolina liver transplant center